Skip to content
Zydus Life Science logo

Zydus Life Science

Zydus Lifesciences Ltd

ZYDUSLIFE NSE
₹1,188.10 −52.50 (−4.23%)
P/E
26.44
View as Markdown
MCP
Close 4 Nov 2026 ₹1,188.10 +251.40 +26.8% 1Y
Start ₹936.70

Key Fundamentals

LargecapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
21.10%
Debt to Equity
0.46
EPS (TTM)
₹44.94
Book Value
₹271.78
Market Cap
—
P/E (TTM)
26.44
P/B
4.37
ROE
21.20%
Dividend Yield
0.08%
EBITDA
₹8,985 Cr
52W High
₹1,266.60
52W Low
₹835.50
Day Range
₹1,182.40 – ₹1,266.60
Volume
49,43,064

Peer Comparison

Healthcare › Pharmaceuticals

Zydus Life Science peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science (this company)
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Median 7 companies₹1,773.4038.81₹1,25,446 Cr4.770.58%16.50%17.80%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

47 Average

Data confidence 100/100

insider_selling

Category scores

Quality
37
Poor
Returns, margins, earnings quality 22% weight
Valuation
62
Good
Cheap vs sector & own history 24% weight
Growth
63
Good
Sales & profit trajectory 9% weight
Financial Health
34
Poor
Solvency, leverage, coverage 9% weight
Momentum
48
Average
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has delivered good profit growth of 18.8% CAGR over last 5 years

No weaknesses listed

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish1711
OscillatorsBullish072
Moving AveragesStrong Bullish109

Key readings

RSI (14)
54.42
Neutral
MACD (12,26,9)
19.12
Bullish
SMA (50)
1,154.26
Bullish
SMA (200)
1,037.60
Bullish

As of

Analyst Rating

Based on 29 analysts
BUY52%

15 of 29 analysts rate Buy, 7 Hold, 7 Sell.

As of

BUY
15
52%
HOLD
7
24%
SELL
7
24%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+11.16%
5Y+12.45%
3Y+16.35%
1Y+16.81%
TTM+21.11%

Net profit

Net profit growth by window
10Y+10.06%
5Y+18.59%
3Y+34.80%
1Y+9.65%
TTM−2.50%

Operating cash flow

Operating cash flow growth by window
10Y+1.12%
5Y−8.46%
3Y−7.66%
1Y−68.78%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+6.48 pp
5Y+9.08 pp
3Y+8.83 pp
1Y+0.85 pp
TTM−0.84 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹9,376 Cr
Mar 2018₹11,905 Cr
Mar 2019₹13,166 Cr
Mar 2020₹14,253 Cr
Mar 2021₹15,102 Cr
Mar 2022₹15,265 Cr
Mar 2023₹17,237 Cr
Mar 2024₹19,547 Cr
Mar 2025₹23,242 Cr
Mar 2026₹27,148 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹1,517 Cr
Mar 2018₹1,810 Cr
Mar 2019₹1,899 Cr
Mar 2020₹1,204 Cr
Mar 2021₹2,185 Cr
Mar 2022₹4,618 Cr
Mar 2023₹2,092 Cr
Mar 2024₹3,973 Cr
Mar 2025₹4,673 Cr
Mar 2026₹5,124 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹1,752 Cr −2.8% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk medium

Zydus Lifesciences trades at ₹1,188.1 as of 2026-11-04 with a market cap of ₹1,25,446 crore and a PE of 26.44x. The company has delivered 32% compounded profit growth over 3 years and 21% TTM sales growth, though TTM profit growth has moderated to 5%. ROE stands at a consistent 21% over the last year with a debt-to-equity ratio of 0.46.

Bull Case 8
  • Strong 3-year compounded profit growth of 32%, significantly above the 10-year average of 11%, indicating an accelerating earnings trajectory
  • TTM revenue growth of 21% is robust and the highest across the reported growth periods, suggesting strong topline momentum
  • Consistent ROE of 21% over the last 1, 3, and 5 years demonstrates sustained capital efficiency well above the cost of equity for most Indian pharma companies
  • ROCE of 19.24% indicates the company generates healthy returns on total capital employed, including debt, reinforcing operational efficiency
  • 5-year compounded sales growth of 12% and profit growth of 19% show expanding margins over the medium term, with profits growing faster than revenue
  • Debt-to-equity of 0.46 is manageable for a pharmaceutical company with diversified operations, leaving room for further investment or acquisitions
  • Stock has delivered a 3-year CAGR of 24%, outperforming its own 10-year CAGR of 11%, reflecting improving market confidence in the business
  • The stock is trading 6.2% below its 52-week high of ₹1,266.6, suggesting it has held up relatively well within its recent range
Bear Case 5
  • TTM profit growth has sharply decelerated to 5% versus the 3-year CAGR of 32%, raising questions about whether earnings momentum is fading
  • PE of 26.44x is elevated relative to the EPS of ₹44.94, and any further slowdown in earnings growth could make the valuation difficult to sustain
  • Dividend yield of just 0.08% offers negligible income return, meaning investors are almost entirely dependent on capital appreciation
  • The gap between TTM sales growth of 21% and TTM profit growth of 5% suggests margin compression or rising costs in the most recent period
  • 10-year stock CAGR of 11% is modest and lags the 3-year CAGR of 24%, indicating that long-term returns have been uneven and the recent rally may not be representative

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Zydus Lifesciences is executing an aggressive diversification strategy with landmark pipeline milestones — notably the first-ever Keytruda biosimilar BLA acceptance and CGT-exclusive ANDA approvals — while delivering 22% revenue growth. Key risks center on the 5 FDA observations at the critical Moraiya facility (45% of US sales) and meaningful margin compression from elevated R&D and expansion spending. The strategic direction is broadly positive, but near-term profitability pressure and FDA remediation execution will be the key variables to watch over the next two quarters.

Headwinds 3
  • FDA flags data integrity issues Oct 13

    US FDA inspection of Moraiya facility (Oct 5-13) ended with 5 observations covering data integrity, undocumented microbial growth, inadequate metal-shaving investigation linked to a Class II recall, and 3 years without FTIR instrument verification. Approximately 45% of US sales come from this facility.

  • EBITDA margin compression Oct 13

    Q1 EBITDA declined 7.6% YoY to ₹1,929.4 crore with margins contracting sharply to 24.1% from 31.8%, despite 22% revenue growth to ₹8,017 crore. North American formulations also dipped 2.6% YoY.

  • Rising opex weighs on profitability Oct 26

    Quarterly R&D spending is now twice the level of three years ago, and Rs 136 billion was invested in capex and acquisitions over FY24-26, 4.5x the FY21-23 level. Rare disease specialty investments may further pressure near-term margins.

Positives 5
  • First Keytruda biosimilar BLA accepted Oct 13

    US FDA accepted the BLA for a proposed pembrolizumab (Keytruda) biosimilar developed with Formycon AG, the first such application publicly accepted. A decision is expected by Q3 CY2027, with an estimated $500 million gross end-market sales opportunity.

  • Estradiol ANDA with CGT exclusivity Oct 26

    Moraiya facility received final US FDA approval for its Estradiol and Levonorgestrel Transdermal System ANDA with 180-day competitive generic therapy exclusivity on October 21, 2026.

  • Sri Lanka pharma plant deal signed Oct 15

    Zydus-Sunshine Healthcare JV signed a BOI agreement to build a USD 20 million pharmaceutical manufacturing facility in Horana, Sri Lanka, targeting operations by 2028.

Neutral 3
  • New statutory auditor appointed Nov 4

    Walker Chandiok & Co LLP (Grant Thornton network) appointed as statutory auditors for a 5-year term from FY27 to FY32, replacing Deloitte Haskins and Sells LLP under mandatory rotation norms.

  • New international business head named Oct 31

    Christoph Stoller appointed as President and Business Unit Head for International Markets, bringing 30+ years of experience including managing a $750 million P&L across 80 countries at a prior role. Dr. Amrut Naik relieved November 7.

  • Zylidac Bio biologics manufacturing pact Oct 21

    Subsidiary Zylidac Bio partnered with Prolific Machines to scale optogenetics-enabled biologics manufacturing from 50L to 250L and commercial GMP levels, leveraging an 83,000 sq ft Emeryville facility.

Quarterly Results

₹ Cr
ZYDUSLIFE quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
5,140
4,369
4,505
5,534
6,208
5,237
5,269
6,528
6,574
6,123
6,864
7,587
8,017
Expenses
3,634
3,223
3,403
3,903
4,124
3,776
3,882
4,402
4,485
4,107
5,048
5,033
6,088
Operating Profit
1,505
1,146
1,102
1,630
2,084
1,461
1,388
2,126
2,088
2,016
1,816
2,554
1,929
OPM %
29%
26%
24%
29%
34%
28%
26%
33%
32%
33%
26%
34%
24%
Other Income
21
54
37.7
156
63
68
57
−139
155
75
26
−263
88
Interest
18
9
20
35
32
25
32
77
85
101
130
123
156
Depreciation
180
184
195
205
215
234
229
238
238
302
360
508
555
PBT
1,329
1,007
926
1,547
1,900
1,271
1,184
1,672
1,921
1,687
1,353
1,660
1,307
Tax %
16%
22%
23%
21%
23%
29%
15%
25%
23%
27%
29%
19%
27%
Net Profit
1,134
803
790
1,246
1,482
920
1,026
1,244
1,521
1,239
1,023
1,341
990
EPS (₹)
10.74
7.91
7.8
11.75
14.11
9.06
10.17
11.64
14.58
12.51
10.36
12.65
9.42

Profit & Loss

₹ Cr
ZYDUSLIFE profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
8,651
9,427
9,376
11,905
13,166
14,253
15,102
15,265
17,237
19,547
23,242
27,148
28,592
Expenses
6,896
7,095
7,474
9,074
10,174
11,455
11,758
11,923
13,378
14,163
16,183
18,673
20,276
Operating Profit
1,756
2,332
1,902
2,831
2,991
2,798
3,344
3,342
3,860
5,384
7,058
8,475
8,316
OPM %
20%
25%
20%
24%
23%
20%
22%
22%
22%
28%
30%
31%
29%
Other Income
45
112
127
111
183
−264
−171
2,581
−422
293
50
−7
−74
Interest
68
53
45
91
194
342
164
127
130
81
166
439
510
Depreciation
287
292
373
539
599
696
725
713
723
764
916
1,408
1,725
PBT
1,446
2,099
1,612
2,312
2,382
1,495
2,285
5,084
2,585
4,832
6,027
6,621
6,007
Tax %
18%
8%
8%
24%
22%
21%
6%
10%
23%
20%
23%
24%
—
Net Profit
1,188
1,964
1,517
1,810
1,899
1,204
2,185
4,618
2,092
3,973
4,673
5,124
4,593
EPS (₹)
11.24
18.89
14.53
17.35
18.06
11.49
20.84
43.83
19.37
38.36
44.97
50.09
44.94
Div. Payout %
21%
17%
22%
20%
19%
30%
17%
6%
31%
8%
24%
2%
—

Balance Sheet

₹ Cr
ZYDUSLIFE balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
102
102
102
102
102
102
102
102
101
101
101
101
Reserves
4,149
5,597
6,858
8,642
10,284
10,273
12,890
16,897
17,415
19,729
23,852
27,011
Borrowings
2,651
2,442
5,207
5,407
7,899
7,986
4,584
4,221
1,195
804
3,213
12,496
Other Liabilities
2,144
2,208
2,937
3,632
4,945
5,115
6,189
6,421
6,851
8,201
9,523
11,065
Total Liabilities
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
Fixed Assets
3,352
3,748
5,755
6,483
12,164
12,230
12,133
12,253
11,521
12,368
13,134
24,106
CWIP
798
951
1,543
1,527
837
742
783
661
1,201
2,423
2,692
3,698
Investments
154
416
435
746
674
765
830
3,288
1,547
1,220
6,412
7,540
Other Assets
4,743
5,235
7,371
9,028
9,556
9,740
10,019
11,439
11,294
12,822
14,451
15,328
Total Assets
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673

Cash Flow

₹ Cr
ZYDUSLIFE cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
994
1,894
1,312
919
1,282
2,505
3,293
2,104
2,689
3,228
6,781
2,117
Investing
−465
−860
−2,872
−974
−3,977
−1,012
−835
1,137
1,178
−1,492
−8,363
−7,895
Financing
−351
−935
2,316
52
1,885
−1,094
−2,549
−868
−4,400
−1,810
1,995
5,807
Net Cash Flow
178
99
756
−3
−811
399
−90
2,373
−534
−75
414
28
Free Cash Flow
498
936
−1,623
−116
236
1,617
2,446
1,050
1,697
2,345
5,139
−530
CFO/OP
79
109
81
54
65
100
109
83
85
84
122
44

Ratios

ZYDUSLIFE financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
67
68
89
98
110
94
76
80
94
97
64
73
Inventory Days
175
158
193
211
208
207
227
245
197
202
227
282
Days Payable
125
154
165
167
149
151
155
141
123
125
131
142
Cash Conversion Cycle
118
71
116
142
169
150
148
184
168
175
160
212
Working Capital Days
6
−1
−34
17
10
−19
−6
19
70
88
3
−40
ROCE %
23%
28%
16%
18%
15%
11%
14%
13%
15%
22%
24%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Zydus Life Science insights

71 extracted metrics across FY06–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 75.01%
  • DIIs 11.28%
  • FIIs 7.05%
  • Public 5.30%
  • Others 1.36%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Zydus Life Science

What does Zydus Lifesciences Ltd do?
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Where is Zydus Lifesciences Ltd (ZYDUSLIFE) listed?
Zydus Lifesciences Ltd trades as ZYDUSLIFE on the NSE and under code 532321 on the BSE.
Which sector does Zydus Lifesciences Ltd belong to?
Zydus Lifesciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd trades at a PE ratio of 26.44 as of 4 Nov 2026, on earnings per share of ₹44.94, against a book value of ₹271.78 per share.
What is the 52-week high and low of Zydus Lifesciences Ltd?
Over the last 52 weeks Zydus Lifesciences Ltd has traded between ₹835.5 and ₹1,266.6 as of 4 Nov 2026.
Does Zydus Lifesciences Ltd pay dividends?
Zydus Lifesciences Ltd has a dividend yield of 0.08%.
What is the Return on Equity (ROE) of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd reported a return on equity of 21.20%. Its debt-to-equity ratio is 0.46.

Company Information

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Website zyduscadila.com
CEO Dr. Sharvil Pankajbhai Patel
Employees 27,917
Listed 18 Apr 2000
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZYDUSLIFE.md for Zydus Lifesciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month